Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Fineline Cube Jul 2, 2026
Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Fineline Cube Jul 2, 2026
Company Digital

Ping An Good Doctor Reports Revenue Decline but Medical Services Growth in 2022

Fineline Cube Mar 23, 2023

China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as Ping An...

Company Digital

JD Healthcare Reports 52.3% Revenue Growth in 2022 Financial Report

Fineline Cube Mar 23, 2023

JD Healthcare, a unit of China’s e-commerce giant JD.com (NASDAQ: JD), released its 2022 financial...

Company

WuXi Biologics Reports 48.4% Revenue Growth in 2022 Financial Report

Fineline Cube Mar 23, 2023

China-based WuXi Biologics (HKG: 2269) released its 2022 financial report for the period ending December...

Company Drug

Advenchen Lab’s AL8326 and Hengrui’s SHR-A1811 Receive Breakthrough Therapy Designations

Fineline Cube Mar 22, 2023

The Center for Drug Evaluation (CDE) website indicates that Advenchen Lab’s AL8326 and Hengrui Pharmaceuticals’...

Company Deals

Merck & Peking University Launch Public Health Training Projects for Young and Middle-Aged Talent

Fineline Cube Mar 22, 2023

Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) and the Peking University School of Public...

Company Drug

Biokin’s BL-B01D1 Receives NMPA Approval for Phase II Solid Tumor Study

Fineline Cube Mar 22, 2023

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has received approval...

Company Drug

Junshi Biosciences’ JS010 Receives NMPA Approval for Migraine Clinical Trials

Fineline Cube Mar 22, 2023

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that it has received clinical trial...

Company Drug

Immunotech Biopharm’s CAR-T-19-D2 Receives NMPA Approval for DLBCL Clinical Trial

Fineline Cube Mar 22, 2023

China-based chimeric antigen receptor T-cell (CAR-T) specialist Immunotech Biopharm Ltd (HKG: 6978) has announced that...

Company Deals

Smith & Nephew Partners with MedMotion for Digital Health Innovation

Fineline Cube Mar 22, 2023

UK-based Smith & Nephew Plc has announced a strategic partnership with China’s Shanghai Fudong Medical...

Company Deals

Aidea Pharma and China Meheco Partner to Expand Medical and Pharmaceutical Services

Fineline Cube Mar 22, 2023

China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced a partnership with China Meheco...

Company

3SBio Inc. Reports 7.5% Revenue Growth in 2022 Financials

Fineline Cube Mar 22, 2023

China-based 3SBio Inc. (HKG: 1530) released its 2022 financial report, recording revenues of RMB 6.859...

Company Deals

Joincare Pharmaceutical Acquires Rights to TaiGen’s PA Endonuclease Inhibitor TG-1000

Fineline Cube Mar 22, 2023

China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced a licensing agreement with...

Company Drug

Reistone Biopharma’s Ivarmacitinib Shows Positive Results in Phase III QUARTZ3 Study

Fineline Cube Mar 22, 2023

Reistone Biopharma Co., Ltd, incubated by Hengrui Pharmaceuticals (SHA: 600276) with USD 100 million in...

Company Deals

Sinopharm Forms Joint Ventures with Foreign Medical Equipment Firms

Fineline Cube Mar 22, 2023

Sinopharm China National Biotech Group Co., Ltd (CNBG) has announced partnerships with two foreign medical...

Company

BeiGene Marks Topping Off of New Biologics Facility in New Jersey

Fineline Cube Mar 22, 2023

China-based biotech BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) held a ceremony to mark the...

Company Deals Digital

Roche Partners with China Resource Medicine to Promote Xofluza in China

Fineline Cube Mar 22, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has entered into a partnership with China-based China Resource...

Company Deals

Jacobio Pharma Partners with Merck to Evaluate CD73 mAb and Keytruda Combination

Fineline Cube Mar 22, 2023

China-based Jacobio Pharma (HKG: 1167) has announced a clinical partnership with Merck, Sharp & Dohme...

Company Drug

Yifan Pharmaceutical’s F-652 Cleared for Phase II Trial in Alcoholic Hepatitis

Fineline Cube Mar 21, 2023

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced that its subsidiary Evive Biotech Ltd’s...

Company Deals

BioNTech Acquires Global Rights to OncoC4’s Anti-CTLA-4 Antibody ONC-392

Fineline Cube Mar 21, 2023

Germany-based mRNA specialist BioNTech SE (NASDAQ: BNTX) has unveiled a licensing deal and collaboration with...

Company Deals

Cygnus Bio Raises Millions in Series C+ Financing for Sequencing Technology

Fineline Cube Mar 21, 2023

Beijing-based second-generation sequencing technology platform Cygnus Bio has reportedly raised “hundreds of millions” of renminbi...

Posts pagination

1 … 571 572 573 … 690

Recent updates

  • Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program
  • Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy
  • Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched
  • TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations
  • TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma – Novel Non-Covalent Approach Shows Enhanced Safety Profile
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Company Drug

TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.